NAD+ and cellular energy: what the science supports

Nicotinamide adenine dinucleotide, or NAD+, is a coenzyme found in every living cell. Its primary role is to facilitate the transfer of electrons during metabolic processes, effectively acting as a bridge in the production of adenosine triphosphate (ATP). ATP provides the chemical energy necessary for fundamental cellular operations, from muscle contraction to DNA repair. As we age, systemic levels of NAD+ naturally decline, a process that researchers have linked to the gradual deterioration of metabolic efficiency.

The biological role of NAD+

NAD+ exists in two forms: NAD+ and NADH. The ratio between these two is a critical indicator of cellular health. Beyond its role in energy production, NAD+ serves as a necessary fuel source for sirtuins, a family of proteins responsible for maintaining genomic stability and regulating inflammation. In studies published in the journal Nature Reviews Molecular Cell Biology, researchers noted that when NAD+ levels drop, the activity of sirtuins diminishes, potentially accelerating cellular senescence. This decline is not merely a byproduct of aging but may be a driver of age-related physiological changes.

Evaluating the clinical evidence

Much of the enthusiasm surrounding NAD+ precursors, such as Nicotinamide Mononucleotide (NMN) and Nicotinamide Riboside (NR), stems from preclinical models. In rodent studies, elevating NAD+ levels has shown improvements in insulin sensitivity and cardiovascular function. However, human data is more nuanced. A study in Science in 2021 indicated that while NMN supplementation increased muscle insulin sensitivity in prediabetic women, it did not significantly alter body composition or blood pressure. Another trial published in The Journal of Clinical Investigation found that while NR effectively raised blood NAD+ levels in older men, the resulting improvements in physical performance were modest rather than transformative.

Delivery methods and bioavailability

A primary challenge in NAD+ therapy is bioavailability. Oral precursors must survive the digestive tract and be converted by the liver before reaching systemic circulation. This has led to increased interest in subcutaneous or intravenous administration, which bypasses the first-pass metabolism of the liver. While these methods achieve higher plasma concentrations, large-scale clinical trials comparing long-term outcomes between oral and injectable routes remain limited. Most current evidence suggests that while elevating NAD+ is safe in the short term, the exact dosage required to achieve specific longevity outcomes is still being refined.

A clinical approach to longevity

Restoring cellular energy is a complex process that requires more than generic supplementation. Factors such as baseline metabolic health, inflammation levels, and existing nutrient deficiencies dictate how an individual responds to therapy. At Kove RX, we manage these variables through physician-led prescribing. Patients receive a thorough evaluation, and treatment plans are adjusted based on objective data and ongoing monitoring through our patient portal. This ensures that interventions like NAD+ therapy are integrated into a broader, evidence-based strategy for long-term health.

This information is provided for educational purposes only and does not constitute medical advice or a provider-patient relationship. You should consult with a licensed clinician before beginning any new medication or supplement protocol to ensure it is appropriate for your specific health needs.